Status:
NOT_YET_RECRUITING
Obinutuzumab in Chinese Real-world Patients With iNHL
Lead Sponsor:
Affiliated Hospital of Nantong University
Conditions:
Lymphomas Non-Hodgkin's B-Cell
Eligibility:
All Genders
18+ years
Brief Summary
This study aims to assess the clinical efficacy and safety of obinutuzumab in Chinese patients with indolent non-Hodgkin B-cell Lymphoma (predominantly Follicular lymphoma and Marginal zone lymphoma) ...
Detailed Description
This study was a prospective, multicenter, non-interventional, real-world study. The study will be divided into two cohorts: Cohort 1 is the younger cohort (aged ≥ 18 and \< 60 years at the start of t...
Eligibility Criteria
Inclusion
- Age: Age ≥ 18 years at the start of treatment;
- Be diagnosed with grade 1-3a follicular Lymphoma, Marginal zone lymphoma;
- Previously untreated or relapsed or refractory patients;
- Patients who started treatment with otuzumab between June 2021 and April 2023.
Exclusion
- Patients currently participating or planning to participate in any interventional clinical trial;
- Patients who, in the opinion of the investigator, are Discomfort for any other reason to participate in this study.
Key Trial Info
Start Date :
July 20 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
July 20 2026
Estimated Enrollment :
400 Patients enrolled
Trial Details
Trial ID
NCT05968001
Start Date
July 20 2023
End Date
July 20 2026
Last Update
August 1 2023
Active Locations (25)
Enter a location and click search to find clinical trials sorted by distance.
1
Changzhou No.2 People's Hospital
Changzhou, Jiangsu, China
2
The First People's hospital of Changzhou
Changzhou, Jiangsu, China
3
Huai'an First People's hospital
Huai'an, Jiangsu, China
4
Jiangyin People's Hospital
Jiangyin, Jiangsu, China